A detailed history of Morgan Stanley transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Morgan Stanley holds 21,708,451 shares of ABUS stock, worth $69 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
21,708,451
Previous 20,960,268 3.57%
Holding current value
$69 Million
Previous $64.8 Million 29.04%
% of portfolio
0.01%
Previous 0.01%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.12 - $4.56 $2.33 Million - $3.41 Million
748,183 Added 3.57%
21,708,451 $83.6 Million
Q2 2024

Oct 17, 2024

BUY
$2.52 - $3.63 $30.6 Million - $44 Million
12,129,971 Added 137.37%
20,960,268 $64.8 Million
Q2 2024

Aug 14, 2024

BUY
$2.52 - $3.63 $30.6 Million - $44 Million
12,129,971 Added 137.37%
20,960,268 $64.8 Million
Q1 2024

Oct 17, 2024

SELL
$2.26 - $2.92 $27.4 Million - $35.4 Million
-12,129,971 Reduced 57.87%
8,830,297 $22.8 Million
Q1 2024

Aug 16, 2024

BUY
$2.26 - $2.92 $4.17 Million - $5.39 Million
1,846,185 Added 26.43%
8,830,297 $22.8 Million
Q1 2024

May 15, 2024

BUY
$2.26 - $2.92 $4.17 Million - $5.39 Million
1,846,185 Added 26.43%
8,830,297 $22.8 Million
Q4 2023

Aug 16, 2024

SELL
$1.69 - $2.54 $23.6 Million - $35.5 Million
-13,976,156 Reduced 66.68%
6,984,112 $17.5 Million
Q4 2023

Feb 13, 2024

BUY
$1.69 - $2.54 $2.91 Million - $4.38 Million
1,722,982 Added 32.75%
6,984,112 $17.5 Million
Q3 2023

Nov 15, 2023

BUY
$1.9 - $2.27 $343,584 - $410,493
180,834 Added 3.56%
5,261,130 $10.7 Million
Q2 2023

Aug 14, 2023

BUY
$2.24 - $3.06 $442,823 - $604,928
197,689 Added 4.05%
5,080,296 $11.7 Million
Q1 2023

May 15, 2023

BUY
$2.23 - $3.1 $10.3 Million - $14.4 Million
4,640,713 Added 1918.49%
4,882,607 $14.8 Million
Q4 2022

Feb 14, 2023

BUY
$1.91 - $2.85 $57,086 - $85,180
29,888 Added 14.1%
241,894 $563,000
Q3 2022

Nov 14, 2022

SELL
$1.88 - $2.88 $13,062 - $20,010
-6,948 Reduced 3.17%
212,006 $405,000
Q2 2022

Oct 27, 2022

BUY
$1.98 - $3.17 $43,110 - $69,020
21,773 Added 11.04%
218,954 $595,000
Q2 2022

Aug 15, 2022

BUY
$1.98 - $3.17 $43,110 - $69,020
21,773 Added 11.04%
218,954 $595,000
Q1 2022

Oct 27, 2022

SELL
$2.42 - $3.98 $52,690 - $86,656
-21,773 Reduced 9.94%
197,181 $587,000
Q1 2022

May 13, 2022

SELL
$2.42 - $3.98 $101,218 - $166,467
-41,826 Reduced 17.5%
197,181 $587,000
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $55,429 - $82,164
17,823 Added 8.06%
239,007 $930,000
Q3 2021

Nov 15, 2021

BUY
$2.65 - $4.62 $586,137 - $1.02 Million
221,184 New
221,184 $950,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $477M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.